Quarterly ResultMay 15, 2026, 03:52 PM
Palomino Labs Q1 Net Loss $(1.24M); Operating Expenses Surge
AI Summary
Palomino Laboratories Inc. reported a net loss of $(1.24) million for the three months ended March 31, 2026, a significant increase from $(0.99) million in the prior year, primarily due to a surge in operating expenses as the company ramps up its development stage operations. The company, a fabless semiconductor firm, incurred substantial general and administrative and research and development costs without generating revenue. Despite the losses and negative cash flow from operations, the company's liquidity is bolstered by $16.98 million from an April private placement, expected to fund operations for at least one year.
Key Highlights
- Q1 2026 net loss was $(1,243,430), up from $(985,169) in Q1 2025.
- Operating expenses increased to $1,243,603 in Q1 2026 from $17,828 in Q1 2025.
- Research and development expenses were $438,240 in Q1 2026, compared to $0 in Q1 2025.
- Cash and cash equivalents stood at $6,656,641 as of March 31, 2026.
- Accumulated deficit reached $(4,424,992) as of March 31, 2026.
- Net cash used in operating activities was $(1,116,468) for Q1 2026.
- Secured $16,975,412 from an April private placement for future operations.
- Company remains in the development stage with no revenue generated.
Price Impact
More from PALX